vs

Side-by-side financial comparison of Expeditors International (EXPD) and Vertex Pharmaceuticals (VRTX). Click either name above to swap in a different company.

Vertex Pharmaceuticals is the larger business by last-quarter revenue ($3.2B vs $2.9B, roughly 1.1× Expeditors International). Vertex Pharmaceuticals runs the higher net margin — 37.3% vs 7.0%, a 30.3% gap on every dollar of revenue. On growth, Vertex Pharmaceuticals posted the faster year-over-year revenue change (9.5% vs -3.3%). Vertex Pharmaceuticals produced more free cash flow last quarter ($348.6M vs $270.3M). Over the past eight quarters, Expeditors International's revenue compounded faster (13.8% CAGR vs 8.9%).

Expeditors International of Washington, Inc. is an American Fortune 500 service-based logistics company with headquarters in Bellevue, Washington. Expeditors generates highly optimized and customized supply chain solutions for clients with unified technology systems integrated through a global network of over 340+ locations in 100+ countries on six continents.

Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.

EXPD vs VRTX — Head-to-Head

Bigger by revenue
VRTX
VRTX
1.1× larger
VRTX
$3.2B
$2.9B
EXPD
Growing faster (revenue YoY)
VRTX
VRTX
+12.9% gap
VRTX
9.5%
-3.3%
EXPD
Higher net margin
VRTX
VRTX
30.3% more per $
VRTX
37.3%
7.0%
EXPD
More free cash flow
VRTX
VRTX
$78.3M more FCF
VRTX
$348.6M
$270.3M
EXPD
Faster 2-yr revenue CAGR
EXPD
EXPD
Annualised
EXPD
13.8%
8.9%
VRTX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EXPD
EXPD
VRTX
VRTX
Revenue
$2.9B
$3.2B
Net Profit
$200.7M
$1.2B
Gross Margin
85.4%
Operating Margin
8.8%
37.8%
Net Margin
7.0%
37.3%
Revenue YoY
-3.3%
9.5%
Net Profit YoY
-14.9%
30.5%
EPS (diluted)
$1.50
$4.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EXPD
EXPD
VRTX
VRTX
Q4 25
$2.9B
$3.2B
Q3 25
$2.9B
$3.1B
Q2 25
$2.7B
$3.0B
Q1 25
$2.7B
$2.8B
Q4 24
$3.0B
$2.9B
Q3 24
$3.0B
$2.8B
Q2 24
$2.4B
$2.6B
Q1 24
$2.2B
$2.7B
Net Profit
EXPD
EXPD
VRTX
VRTX
Q4 25
$200.7M
$1.2B
Q3 25
$222.3M
$1.1B
Q2 25
$183.6M
$1.0B
Q1 25
$203.8M
$646.3M
Q4 24
$235.9M
$913.0M
Q3 24
$229.6M
$1.0B
Q2 24
$175.5M
$-3.6B
Q1 24
$169.2M
$1.1B
Gross Margin
EXPD
EXPD
VRTX
VRTX
Q4 25
85.4%
Q3 25
86.5%
Q2 25
86.3%
Q1 25
86.9%
Q4 24
85.5%
Q3 24
85.8%
Q2 24
85.9%
Q1 24
87.3%
Operating Margin
EXPD
EXPD
VRTX
VRTX
Q4 25
8.8%
37.8%
Q3 25
10.0%
38.6%
Q2 25
9.3%
38.8%
Q1 25
10.0%
22.7%
Q4 24
10.2%
35.2%
Q3 24
10.1%
40.3%
Q2 24
9.2%
-132.9%
Q1 24
9.7%
42.4%
Net Margin
EXPD
EXPD
VRTX
VRTX
Q4 25
7.0%
37.3%
Q3 25
7.7%
35.2%
Q2 25
6.9%
34.8%
Q1 25
7.6%
23.3%
Q4 24
8.0%
31.4%
Q3 24
7.7%
37.7%
Q2 24
7.2%
-135.8%
Q1 24
7.7%
40.9%
EPS (diluted)
EXPD
EXPD
VRTX
VRTX
Q4 25
$1.50
$4.64
Q3 25
$1.64
$4.20
Q2 25
$1.34
$3.99
Q1 25
$1.47
$2.49
Q4 24
$1.68
$3.62
Q3 24
$1.63
$4.01
Q2 24
$1.24
$-13.92
Q1 24
$1.17
$4.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EXPD
EXPD
VRTX
VRTX
Cash + ST InvestmentsLiquidity on hand
$1.3B
$6.6B
Total DebtLower is stronger
Stockholders' EquityBook value
$2.4B
$18.7B
Total Assets
$4.9B
$25.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EXPD
EXPD
VRTX
VRTX
Q4 25
$1.3B
$6.6B
Q3 25
$1.2B
$6.3B
Q2 25
$1.2B
$6.4B
Q1 25
$1.3B
$6.2B
Q4 24
$1.1B
$6.1B
Q3 24
$1.3B
$6.5B
Q2 24
$1.3B
$5.8B
Q1 24
$1.4B
$10.2B
Stockholders' Equity
EXPD
EXPD
VRTX
VRTX
Q4 25
$2.4B
$18.7B
Q3 25
$2.3B
$17.3B
Q2 25
$2.2B
$17.2B
Q1 25
$2.3B
$16.5B
Q4 24
$2.2B
$16.4B
Q3 24
$2.4B
$15.6B
Q2 24
$2.2B
$14.8B
Q1 24
$2.2B
$18.5B
Total Assets
EXPD
EXPD
VRTX
VRTX
Q4 25
$4.9B
$25.6B
Q3 25
$4.8B
$24.9B
Q2 25
$4.8B
$24.0B
Q1 25
$4.8B
$22.9B
Q4 24
$4.8B
$22.5B
Q3 24
$5.2B
$22.2B
Q2 24
$4.8B
$20.1B
Q1 24
$4.5B
$23.9B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EXPD
EXPD
VRTX
VRTX
Operating Cash FlowLast quarter
$283.3M
$498.0M
Free Cash FlowOCF − Capex
$270.3M
$348.6M
FCF MarginFCF / Revenue
9.5%
10.9%
Capex IntensityCapex / Revenue
0.5%
4.7%
Cash ConversionOCF / Net Profit
1.41×
0.42×
TTM Free Cash FlowTrailing 4 quarters
$953.4M
$3.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EXPD
EXPD
VRTX
VRTX
Q4 25
$283.3M
$498.0M
Q3 25
$201.4M
$1.2B
Q2 25
$179.2M
$1.1B
Q1 25
$342.6M
$818.9M
Q4 24
$249.7M
$584.6M
Q3 24
$90.0M
$1.4B
Q2 24
$126.8M
$-3.8B
Q1 24
$256.9M
$1.3B
Free Cash Flow
EXPD
EXPD
VRTX
VRTX
Q4 25
$270.3M
$348.6M
Q3 25
$190.3M
$1.1B
Q2 25
$163.3M
$927.4M
Q1 25
$329.5M
$778.2M
Q4 24
$239.7M
$492.0M
Q3 24
$77.7M
$1.3B
Q2 24
$118.8M
$-3.8B
Q1 24
$246.7M
$1.2B
FCF Margin
EXPD
EXPD
VRTX
VRTX
Q4 25
9.5%
10.9%
Q3 25
6.6%
37.0%
Q2 25
6.2%
31.3%
Q1 25
12.4%
28.1%
Q4 24
8.1%
16.9%
Q3 24
2.6%
47.0%
Q2 24
4.9%
-144.5%
Q1 24
11.2%
46.0%
Capex Intensity
EXPD
EXPD
VRTX
VRTX
Q4 25
0.5%
4.7%
Q3 25
0.4%
3.3%
Q2 25
0.6%
4.9%
Q1 25
0.5%
1.5%
Q4 24
0.3%
3.2%
Q3 24
0.4%
2.4%
Q2 24
0.3%
2.6%
Q1 24
0.5%
2.5%
Cash Conversion
EXPD
EXPD
VRTX
VRTX
Q4 25
1.41×
0.42×
Q3 25
0.91×
1.15×
Q2 25
0.98×
1.04×
Q1 25
1.68×
1.27×
Q4 24
1.06×
0.64×
Q3 24
0.39×
1.31×
Q2 24
0.72×
Q1 24
1.52×
1.19×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EXPD
EXPD

Customs Brokerage And Other Services$1.1B40%
Airfreight Services$1.1B39%
Ocean Freight And Ocean Services$611.4M21%

VRTX
VRTX

TRIKAFTAKAFTRIO$2.6B81%
ALYFTREK$380.1M12%
Manufactured Product Other$237.4M7%

Related Comparisons